Lyell Immunopharma Announces Appointment of New Chief Financial and Business Officer

South San Francisco, CA, March 9, 2026 – Lyell Immunopharma, Inc. (Nasdaq: LYEL), a leading biotechnology company focused on developing curative therapies for cancer, has announced a significant leadership change that could impact the company’s strategic direction and financial management.

Key Developments

• Appointment of Smital Shah as Chief Financial and Business Officer: Effective March 9, 2026, Smital Shah will assume the role of Chief Financial and Business Officer and principal financial officer. This appointment was approved by the company’s Board of Directors on March 6, 2026. Dr. Lynn Seely, the company’s President and CEO, had previously served as interim principal financial officer.
• Executive Compensation Details: Under the terms of her offer letter, Ms. Shah will receive an initial annual base salary of \$500,000 and is eligible for a target annual bonus of up to 50% of her base salary, based on performance objectives set by the Board.
• Equity Incentive: Ms. Shah will be granted a stock option for 140,000 shares of Lyell common stock, with an exercise price equal to the fair market value on the date of grant. The options vest 25% on the one-year anniversary of her start date, with the remainder vesting in equal monthly installments over the next three years.
• Inclusion in Officer Severance Plan: Ms. Shah will participate as a Tier I Employee in the company’s Officer Severance Plan, providing her with additional security and aligning her interests with those of shareholders.

Background and Experience of Smital Shah

• Ms. Shah, age 49, brings extensive finance and business development experience in the biotech sector. She has served as a consultant to Lyell since February 2026 and has advised multiple biotech and life sciences companies since January 2023.
• From October 2014 to December 2022, she was Chief Business and Financial Officer at ProQR Therapeutics (Nasdaq: PRQR), where she oversaw finance, communications, commercial strategy, business development, and legal.
• Prior to ProQR, she managed Gilead Sciences’ multi-billion-dollar debt, cash, and investment portfolios, and was previously an investment banker at Leerink Partners and JP Morgan, focusing on capital raising and strategic transactions in biotech.
• Earlier in her career, Ms. Shah held R&D roles at Johnson & Johnson.
• She holds a B.S. in Chemical Engineering from the University of Mumbai, an M.S. in Chemical Engineering from Virginia Tech, and an M.B.A. in Finance from UC Berkeley’s Haas School of Business.
• She has served on the Board of Directors of Pliant Therapeutics and as Chair of the Audit Committee at Graphite Bio until its merger with LENZ Therapeutics in March 2024.

Shareholder-Relevant and Potentially Price-Sensitive Information

• Leadership Change: The appointment of a highly experienced Chief Financial and Business Officer is a significant event for Lyell, especially as the company seeks to advance its pipeline and attract investment. Ms. Shah’s track record in capital markets, strategic transactions, and financial leadership at publicly traded biotech firms may enhance investor confidence and influence the company’s valuation.
• Alignment of Interests: The substantial equity grant and participation in the Officer Severance Plan ensure Ms. Shah’s interests are closely tied to those of shareholders, which could positively affect long-term strategic decisions and shareholder value.
• Potential Strategic Moves: Given Ms. Shah’s background in M&A, business development, and capital raising, her appointment may signal an increased focus on strategic transactions, partnerships, or further financing, which are all potentially price-moving events.
• Stability and Governance: The transition from interim financial leadership to a permanent, highly qualified executive may be viewed positively by the market, enhancing perceptions of stability and governance at Lyell.

Additional Notes

• Lyell and Ms. Shah entered into the company’s standard indemnification agreement, providing legal protections typical for executives at public companies.
• The full text of Ms. Shah’s offer letter is available as an exhibit to the company’s latest SEC filing.
• There were no other material changes or announcements made in this 8-K filing.

Conclusion

The appointment of Smital Shah as Chief Financial and Business Officer brings deep industry expertise, proven leadership, and a focus on value creation to Lyell Immunopharma. Investors should monitor future communications for any strategic initiatives or financial moves led by Ms. Shah, as these could materially impact the company’s share price and long-term outlook.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The information provided is based on the company’s public filings as of the date indicated and may be subject to change.

View Lyell Immunopharma, Inc. Historical chart here